NCT05688592 Usefulness of PET-CT for Invasive Fungal Infection
| NCT ID | NCT05688592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Puerta de Hierro University Hospital |
| Condition | Invasive Fungal Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 224 participants |
| Start Date | 2023-04-27 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 224 participants in total. It began in 2023-04-27 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are: 1. Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension/staging and monitoring of response/follow-up ? 2. Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).
Eligibility Criteria
Inclusion criteria: * 18-year-old adult patients * who are admitted with a diagnosis of invasive fungal infection * who able to undergo a one 18F-FDG PET-CT * who give their informed consent. Exclusion criteria: * concomitant active bacterial infection likely to produce uptake in organs and tissues * recent surgery in the area of the IFI (in the previous 3 months) * other medical conditions that interfere with the development of the study ( e.g., inability to tolerate the performance of the test during the required time, pregnancy) * terminal situation.
Contact & Investigator
Ana Fernández Cruz, MDPhD
PRINCIPAL INVESTIGATOR
Hospital Puerta de Hierro-Majadahonda
Frequently Asked Questions
Who can join the NCT05688592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Invasive Fungal Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05688592 currently recruiting?
Yes, NCT05688592 is actively recruiting participants. Contact the research team at a.gutierrezv@hotmail.com for enrollment information.
Where is the NCT05688592 trial being conducted?
This trial is being conducted at Majadahonda, Spain, Barcelona, Spain, Barcelona, Spain, Granada, Spain and 10 additional locations.
Who is sponsoring the NCT05688592 clinical trial?
NCT05688592 is sponsored by Puerta de Hierro University Hospital. The principal investigator is Ana Fernández Cruz, MDPhD at Hospital Puerta de Hierro-Majadahonda. The trial plans to enroll 224 participants.